{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:14:47Z","timestamp":1779210887853,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["CIC 1402"],"award-info":[{"award-number":["CIC 1402"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejca.2020.05.020","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T05:06:47Z","timestamp":1594530407000},"page":"107-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Ponatinib in childhood Philadelphia chromosome\u2013positive leukaemias: an international registry of childhood chronic myeloid leukaemia study"],"prefix":"10.1016","volume":"136","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne B.","family":"Versluys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Nelken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.05.020_bib1","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.020_bib2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2020.05.020_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.05.020_bib4","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.05.020_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.05.020_bib6","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2020.05.020_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitor: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.05.020_bib8","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.05.020_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2020.05.020_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.ejca.2020.05.020_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2020.05.020_bib12","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/pbc.25551","article-title":"Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib","volume":"62","author":"Nickel","year":"2015","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.ejca.2020.05.020_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16338","article-title":"Experience with ponatinib in paediatric patients with leukaemia","volume":"189","author":"Rossoff","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2020.05.020_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12185-018-02571-0","article-title":"Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia","volume":"109","author":"Tachibana","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ejca.2020.05.020_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clml.2016.04.017","article-title":"Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia?","volume":"16","author":"DeFilipp","year":"2016","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ejca.2020.05.020_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.05.020_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejca.2020.05.020_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.05.020_bib19","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Canc"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:16Z","timestamp":1760732896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":19,"alternative-id":["S0959804920302872"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponatinib in childhood Philadelphia chromosome\u2013positive leukaemias: an international registry of childhood chronic myeloid leukaemia study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}